Amal Imbulgoda1, Anthony MacLean2, John Heine2, Sebastien Drolet3, Michael M Vickers4. 1. The Department of Oncology, University of Calgary, Calgary, Alta. 2. The Department of Surgery, University of Calgary, Calgary, Alta. 3. The Department of Surgery, Université Laval, Québec, Que. 4. The Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ont.
Abstract
BACKGROUND: Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known. METHODS: We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012. RESULTS: We reviewed the records of 87 patients with inoperable colorectal cancer who received SEMS during our study period. Nine perforations occurred in total: 4 of 30 (13%) patients who received no chemotherapy, 3 of 47 (6%) who received chemotherapy but no bevacizumab, and 2 of 10 (20%) who received chemotherapy and bevacizumab. These two patients received bevacizumab with FOLFIRI after SEMS placement, and they had peritoneal disease. CONCLUSION: Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.
BACKGROUND: Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known. METHODS: We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012. RESULTS: We reviewed the records of 87 patients with inoperable colorectal cancer who received SEMS during our study period. Nine perforations occurred in total: 4 of 30 (13%) patients who received no chemotherapy, 3 of 47 (6%) who received chemotherapy but no bevacizumab, and 2 of 10 (20%) who received chemotherapy and bevacizumab. These two patients received bevacizumab with FOLFIRI after SEMS placement, and they had peritoneal disease. CONCLUSION: Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.
Authors: Laura E Targownik; Brennan M Spiegel; Jonathan Sack; Oscar J Hines; Gareth S Dulai; Ian M Gralnek; James J Farrell Journal: Gastrointest Endosc Date: 2004-12 Impact factor: 9.427
Authors: George A Poultsides; Elliot L Servais; Leonard B Saltz; Sujata Patil; Nancy E Kemeny; Jose G Guillem; Martin Weiser; Larissa K F Temple; W Douglas Wong; Phillip B Paty Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: J E van Hooft; P Fockens; A W Marinelli; R Timmer; A M van Berkel; P M Bossuyt; W A Bemelman Journal: Endoscopy Date: 2008-03 Impact factor: 10.093
Authors: Johanna C Bendell; Tamara Sauri; Antonio Cubillo Gracián; Rafael Alvarez; Carlos López-López; Pilar García-Alfonso; Maen Hussein; Maria-Luisa Limon Miron; Andrés Cervantes; Clara Montagut; Cristina Santos Vivas; Alberto Bessudo; Patricia Plezia; Veerle Moons; Johannes Andel; Jaafar Bennouna; Andre van der Westhuizen; Leslie Samuel; Simona Rossomanno; Christophe Boetsch; Angelika Lahr; Izolda Franjkovic; Florian Heil; Katharina Lechner; Oliver Krieter; Herbert Hurwitz Journal: Oncologist Date: 2019-09-30
Authors: Anouk E J Latenstein; Mathijs P Hendriks; Emo E van Halsema; Jeanin E van Hooft; Anne-Marie van Berkel Journal: Case Rep Gastroenterol Date: 2017-11-29
Authors: Johanna C Bendell; Tamara Sauri; Antonio Cubillo Gracián; Rafael Alvarez; Carlos López-López; Pilar García-Alfonso; Maen Hussein; Maria-Luisa Limon Miron; Andrés Cervantes; Clara Montagut; Cristina Santos Vivas; Alberto Bessudo; Patricia Plezia; Veerle Moons; Johannes Andel; Jaafar Bennouna; Andre van der Westhuizen; Leslie Samuel; Simona Rossomanno; Christophe Boetsch; Angelika Lahr; Izolda Franjkovic; Florian Heil; Katharina Lechner; Oliver Krieter; Herbert Hurwitz Journal: Oncologist Date: 2019-09-30